# Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer

> **NCT00216125** · PHASE3 · COMPLETED · sponsor: **Nasser Hanna, M.D.** · enrollment: 243 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **RADIATION:** Radiation
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00216125
- **Lead sponsor:** Nasser Hanna, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2006-06
- **Final completion:** 2008-03
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2016-03-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216125, "Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00216125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*